Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
osivelotor + famotidine
- Development stage
- Unknown
- Lead developer
- Pfizer
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Osivelotor + famotidine is a combination drug composed of osivelotor, a hemoglobin S polymerization inhibitor, and famotidine, a selective histamine H2 receptor antagonist that decreases gastric acid production. Osivelotor is being developed for the treatment of sickle cell disease, while famotidine is widely used to manage conditions involving excessive gastric acid, such as peptic ulcer disease and gastroesophageal reflux disease. The rationale for this combination would be to address the primary disease while also managing associated gastrointestinal side effects or comorbidities.
02
Targets
Hemoglobin subunit alpha N-terminal valineHRH2 (Histamine H2 Receptor)
Beyond the preview
Go deeper on osivelotor + famotidine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on osivelotor + famotidine.